Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2003

View Archived Issues

Efficacy of oral recombinant L. lactis vector expressing the HIV Env gene as an HIV vaccine in mice

DakoCytomation licenses novel prostate cancer markers

Oral efficacy study completed for small-molecule inhibitor of PTP1B

Avidex and Dow to develop biotargeted radiopharmaceuticals for cancer

Phase I/II trial of bone graft product cleared to begin

Orphan drug status granted to Hemoxin for sickle cell disease

Progress reported in development of DCtag vaccine technology

Partial clinical hold on phase III Oncophage trials

ICAgen completes enrollment in phase II trial of ICA-17043

Acambis and Cangene collaborate on West Nile hyperimmune development

CAT and Xerion enter into drug development agreement

GenVec completes Diacrin merger

Aphios marine microorganism library to be tested against SARS

Axcan licenses Itax from Abbott

Quorex and Idec enter collaboration

Phase II doripenem trial completes enrollment ahead of schedule

Two series of semaphorin inhibitors identified by Sumitomo researchers

Adenosine A1 receptor allosteric enhancers claimed by U. of Virginia scientists

New glucocorticoids for inflammatory and allergic disorders covered by GSK patent

Muscagen presents novel adenosine A3 agonists with potential as cardioprotectants

Glucocorticoid receptor modulators for obesity, diabetes, psychiatric disorders, etc.

Kylix describes new Tie-2/KDR inhibitors and their use

Spermine analogue displays potent central antinociceptive effects in rat model

Efficacy of new NMDA NR2B antagonist in models of chronic and neuropathic pain

Antihyperalgesic effects of EP1 receptor antagonists

Pfizer to market olmesartan in markets in Asia, Oceania and Latin America

Preservation of beta-cell function following treatment with NN-414

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026